Sequential Nephron Blockade in Acute Heart Failure

Acute Heart Failure Clinical Trial

Official title:

Early Sequential Nephron Blockade Versus Standard Diuretic Treatment in Acute Heart Failure

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04163588
• Other study ID #: SNB01
• Status: Recruiting
• Phase: Phase 3
• Start date: October 1, 2019
• Est. completion date: December 31, 2020

Study information

• Verified date: November 2019
• Source: Policlinico Casilino ASL RMB
• Contact: Gennaro Cice, MD
• Phone: 0039330915294
• Email: gennarocice[@]hotmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Background - Volume overload is an important clinical target in acute heart failure management (AHF), typically addressed using loop diuretics. An important and challenging subset of heart failure patients exhibit fluid overload despite significant doses of loop diuretics. One approach to overcome loop diuretic resistance is the addition of a thiazide-type diuretic to produce diuretic synergy via "sequential nephron blockade". Although potentially able to induce diuresis in patients otherwise resistant to high doses of loop diuretics, this strategy has not been subjected to large-scale clinical trials to establish safety and clinical efficacy.

Methods - Our trial is a multicentric, double blind, randomized clinical study, aiming to recruit 310 patients with AHF and clinically evident volume overload. Study participants are randomized to receive a standard diuretic therapy (intravenous loop diuretics as recommended by current guidelines plus placebo) or SNB therapy (loop diuretics plus oral metolazone at the dose of 5/10 mg once daily) on top of standard medical therapy. Mineralocorticoid antagonists will be used in association with the two regimens according to blood potassium level and kidney function at the discretion of the treating physician. The primary endpoint is defined as the change in the serum creatinine level and the change in weight, considered both as a bivariate response and with their single components, between the time of randomization and 72 hours after randomization. Secondary endpoints include global well-being and dyspnoea assessed by a visual-analogue scale, changes in body weight and net fluid loss, proportion of patients free from congestion, treatment failure, changes in biomarker levels and the composite of death, rehospitalization, or an emergency room visit within 60 days, as well as the composite of total number of days hospitalized or death during the 60 days after randomization.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 310
• Est. completion date: December 31, 2020
• Est. primary completion date: October 31, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 99 Years

Eligibility

Inclusion Criteria:

• Signed written informed consent must be obtained before any study assessment is performed

• Male or female patients 18 years of age or older

• An elective or emergency hospital admission with clinical diagnosis of decompensated HF with at least one clinical sign of volume overload (e.g. oedema (score 2 or more), ascites confirmed by echography or pleural effusion confirmed by chest X-ray or echography) Plasma NT-proBNP levels >1000 ng/mL or BNP levels >250 ng/mL at the time of screening.

Assessed LVEF by any imaging technique; i.e. echocardiography, catheterization, nuclear scan or magnetic resonance imaging within 12 months of inclusion

Exclusion Criteria:

• Concurrent diagnosis of an acute coronary syndrome defined as typical chest pain in addition to a troponin rise above the 99th percentile and/or electrocardiographic changes suggestive of cardiac ischemia

• History of congenital heart disease requiring surgical correction

• History of a cardiac transplantation and/or ventricular assist device

• Systolic blood pressure <90 mmHg or mean arterial pressure <65 mmHg at the moment of admission

• Estimated glomerular filtration rate <20 mL/min/1.73m² at screening

• Use of renal replacement therapy or ultrafiltration at any time before study inclusion

• Treatment with metolazone during the index hospitalization and prior to randomization

• Exposure to nephrotoxic agents (i.e. contrast dye) anticipated within the next 3 days

• Use of any non-protocol defined diuretic agent with the exception of mineralocorticoid receptor antagonists.

• Current use of sodium-glucose transporter-2 inhibitors

• Subjects who are pregnant or breastfeeding

Related Conditions & MeSH terms

• Acute Heart Failure
• Heart Failure

Intervention

Drug:
• Metolazone
Study participants receive loop diuretics plus oral metolazone at a dose of 5/10 mg once daily
• Loop Diuretics
Study participants receive a standard diuretic strategy (intravenous loop diuretics as recommended by current guidelines plus placebo)

Locations

Country	Name	City	State
Italy	Policlinico Casilino	Rome	Lazio

Sponsors (3)

Lead Sponsor	Collaborator
Policlinico Casilino ASL RMB	IRCCS San Raffaele, Umberto I Hospital, Nocera Inferiore

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	change in the serum creatinine level and the change in weight, considered both as a bivariate response and with their single components	The bivariate response will be displayed on a two-dimensional grid with individual data points for each patient representing paired changes in both creatinine (inmg/dL) and weight (in kilograms) 76 hours after randomization. A confidence region for the average difference between treatment arms in this bivariate response can be described as an ellipse, and the 2 treatment arms will be compared statistically with the use of the Hotelling T- square, which is a multivariate analog of the 2-sample t test used with a single continuous variable (Ann Math Stat. 1931; 2:360-78). Evaluating these 2 important responses to treatment as a bivariate end point reflects clinically important responses to therapy and avoids the requirement of making adjustments in sample size to prevent a type 1 error that would be necessary if the end points were considered separately (Eur J Heart Fail. 2003; 5:717-23).	72 hours
Secondary	global well-being assessment by a visual-analogue scale	Global well-being is assessed with the use of a visual-analogue scale that ranged from 0 to 100, with higher scores indicating greater well-being (Chest 1999;116:1208-17)	72 hours
Secondary	body weight assessment	total changes in body weight in kilograms	72 hours
Secondary	congestion	proportion of patients who were free from congestion (defined as jugular venous pressure of <8 cm, with no orthopnoea and with trace peripheral oedema or no oedema)	72 hours
Secondary	treatment failure	death, worsening/persistent HF, need for dialysis, crossover from standard pharmacologic care to sequential nephron blockade or the occurrence of a serious adverse event during the first 7 days from admission	7 days
Secondary	Biomarkers	changes in NT-proBNP levels (in pg/mL) at 72 hours, day 7 or discharge	72 hours, 7 days or discharge
Secondary	clinical end-point	composite of death, rehospitalization, or an emergency room visit within 60 days	60 days
Secondary	hospitalization-death	composite of total number of days hospitalized or dead during the 60 days after randomization	60 days
Secondary	Total net fluid loss	total urinary output (in milliliters) from randomization to 76 hours	76 hours
Secondary	dyspnea assessment by a visual-analogue scale	Dyspnea is assessed with the use of a visual-analogue scale that ranged from 0 to 100, with higher scores indicating less dyspnea (Chest 1999;116:1208-17)	76 hours